Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts

Novel Histamine Receptor Family Antagonists by Fragment Screening and Molecular Modelling

Mark Slack, Group Leader Cellular Assays, Evotec, speaking at MedChem Europe
Date Posted: Sunday, June 12, 2011
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Related Content

Evotec Wins Research Grant to Advance H3 Receptor Antagonist Programme into the Clinic
A EUR 1.5 million BMBF grant will advance the H3 receptor antagonist programme through Phase I clinical studies.
Tuesday, April 27, 2010
Evotec and Boehringer Ingelheim Extend and Broaden Research Collaboration
Strategic research collaboration continues for another 4 years at a value of EUR 15 million plus milestones and royalties
Monday, November 09, 2009
Evotec Receives a EUR 2.5 Million Milestone Payment in its Research Collaboration with Boehringer Ingelheim
Evotec AG today announced that it has achieved another milestone in its research collaboration with Boehringer Ingelheim.
Thursday, October 22, 2009
Procter & Gamble Selects Evotec as Provider of Pharmaceutical Discovery and Chemical Development Services
P&GP will access a wide range of discovery and preclinical expertise offered by Evotec, ranging from assay development, screening, medicinal and computational chemistry to scale-up and pharmaceutical manufacture.
Monday, July 25, 2005
Evotec OAI and Novartis Pharma AG Sign Lead Discovery Collaboration

Thursday, April 10, 2003
Evotec OAI collaboration with KeyNeurotek and IMTM

Wednesday, January 15, 2003
Evotec OAI Names President of Discovery Services

Tuesday, December 10, 2002
Evotec OAI Enters into Agreement With Venture Capital Firm

Thursday, November 14, 2002
Scientific News
Combining Chemotherapy With Immune-Blocking Drug Could Stop Cancer Growing Back
Giving patients a drug that blocks part of the immune system from going into overdrive might help prevent cancer coming back in some people.
Researchers Pioneer Use of Capsules to Save Materials
Wax capsule delivery systems can simplify a wide range of chemistry transformations.
Photoredox Catalyst Unlocks New Pathways for Nickel Chemistry
Using a light-activated catalyst, researchers have unlocked a new pathway in nickel chemistry to construct carbon-oxygen (C-O) bonds that would be highly valuable to pharmaceutical and agrochemical industries.
Scientists Determine How Antibiotic Gains Cancer-Killing Sulfur Atoms
In a discovery with implications for future drug design scientists have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity.
Familiar Drugs May Block Ebola Virus Infection
A well-known class of molecules, many of which are already in use therapeutically, may be able to block the Ebola virus’s entry into cells and halt the disease in its tracks, according to researchers at the University of Illinois at Chicago.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Common Class of ‘Channel Blocking’ Drugs May Find a Role in Cancer Therapy
Discoveries in fruit flies prompt unusual treatment of patient with metastatic disease.
Common Medications Could Delay Brain Injury Recovery
Drugs used to treat common complaints could delay the recovery of brain injury patients according to research by University of East Anglia (UEA) and University of Aberdeen scientists, published today in Brain Injury.
Scientists Make Strides in Therapy Preventing Addiction Relapse
Single Injection of Drug Candidate Prevents Meth Relapse in Animal Models.
New Clot-Busting Treatments Target Number One Killer
Australian researchers funded by the National Heart Foundation are a step closer to a safer and more effective way to treat heart attack and stroke via nanotechnology.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!